Announcement on Obtaining Drug Registration Certificate for Class 2 Improved New Drug Levetiracetam Sustained-Release Granules

Hangzhou Bio-Sincerity Pharma-Tech Co., Ltd.·July 17, 2026·2 pages

✨ AI Summary

Hangzhou BaiCheng Pharmaceutical Technology Co., Ltd. announces its subsidiary has obtained a drug registration certificate for Levetiracetam Sustained-Release Granules. This improved new drug is for adjunctive treatment of partial-onset seizures in patients aged 12 and above. The granules offer advantages for pediatric and dysphagic patients, improving compliance. The company expects no significant short-term impact on performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 301096

Securities Abbreviation: BaiCheng Pharmaceutical

Announcement No.: 2026-035

Hangzhou BaiCheng Pharmaceutical Technology Co., Ltd.

Announcement on Obtaining Drug Registration Certificate for Class 2 Improved New Drug Levetiracetam Sustained-Release Granules

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the contents of this announcement, and are jointly and severally liable for any false records, misleading statements, or material omissions in this announcement.

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.